TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7613554
Drug: Moguisteine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moguisteine (100 mg t.i.d.)
Study: 7613554
Drug: Codeine 15
Normalized name: codeine 15 MG
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine 15 mg (t.i.d.)
Study: 7613554
Drug: Codeine 30
Normalized name: codeine 30 MG
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine 30 mg (t.i.d.)
Study: 576296
Drug: Constant intravenous
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant intravenous infusion of regular insulin (2 units/hour)
Study: 576296
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (two thirds of daily maintenance doses)
Study: 576296
Drug: Preoperative NPH
Normalized name: INSULIN,NPH,BEEF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative NPH insulin and 1 unit/hour insulin administration
Study: 29209926
Drug: Prophylactic phenylephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic phenylephrine infusion (50 μg·min‐1, titrated)
Study: 29209926
Drug: Phenylephrine bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine bolus dosing (100 μg)
Study: 24048950
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of irbesartan 300 mg film-coated tablet
Study: 18219299
Drug: High-sodium diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sodium diet with ACE inhibitor (HS-ACEi; enalapril 20 mg/day)
Study: 8694217
Drug: 2% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lignocaine 2 ml with 1:200,000 adrenaline
Study: 1398272
Drug: Intracervical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical prostaglandin E2 gel (0.5 mg)
Study: 4025314
Drug: Bovine heparin
Normalized name: BOVINE HEPARIN
DrugBank: Heparin, bovine (DB15404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine heparin #1
Study: 4025314
Drug: Bovine heparin
Normalized name: BOVINE HEPARIN
DrugBank: Heparin, bovine (DB15404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine heparin #2
Study: 4025314
Drug: Porcine gut
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine gut heparin
Study: 21194762
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose tirofiban
Study: 15892438
Drug: Generic health-related
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic health-related instruments administered first (SF-36 followed by HADS)
Study: 15892438
Drug: Vision-targeted instruments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vision-targeted instruments administered first (NEI-VFQ followed by SST-VPVS)
Study: 12684289
Drug: BPV plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPV plus conventional therapy
Study: 10098826
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of generalized anxiety, panic, and dysthymic disorders
Study: 9345409
Drug: Copolymer I
Normalized name: Copolymer I (synthetic peptide)
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copolymer I (20 mg daily subcutaneous injection)
Study: 2050174
Drug: Peroral captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peroral captopril (25 mg)
Study: 6410442
Drug: tryptophan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: tryptophan (1 g)
Study: 31010449
Drug: Integrated, exposure-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated, exposure-based treatment (COPE)
Study: 31010449
Drug: Non-exposure-based, SUD-only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-exposure-based, SUD-only treatment (RP)
Study: 27028980
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg/d, up-titrated to 30 mg/d)
Study: 24690571
Drug: Cerebral perfusion
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebral perfusion pressure-targeted therapy (n = 55)
Study: 24690571
Drug: Intracranial pressure-targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracranial pressure-targeted therapy (n = 55)
Study: 22240353
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg RES capsule daily for 3 months
Study: 17549295
Drug: Low-dose HT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose HT (1 mg 17ss-oestradiol + 0.5 mg norethisterone acetate) (n = 50)
Study: 17549295
Drug: Conventional-dose HT
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose HT (2 mg 17ss-oestradiol and 1 mg NETA) (n = 50)
Study: 17549295
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg) (n = 51)
Study: 17549295
Drug: Raloxifene (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (60 mg) (n = 51)
Study: 9863873
Drug: Monotherapy arms
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monotherapy arms (zidovudine, zalcitabine, didanosine)
Study: 9863873
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies (zidovudine, zalcitabine, didanosine)
Study: 8568176
Drug: Hysterosonography with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hysterosonography with sterile saline injection using a novel catheter
Study: 6201083
Drug: Dextran infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran infusion with hapten blockade (monovalent dextran-1)
Study: 16284385
Drug: Broccoli sprouts
Normalized name: broccoli sprout extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli sprouts infusion containing 400 micromol glucoraphanin
Study: 16284385
Drug: Broccoli sprouts
Normalized name: broccoli sprout extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli sprouts infusion containing < 3 micromol glucoraphanin
Study: 31464548
Drug: Single SUI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single SUI treatment (Group 1)
Study: 31464548
Drug: Two SUI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two SUI treatments (Group 2)
Study: 23210360
Drug: Microcurrent reflexotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcurrent reflexotherapy (MCRT) combined with cortexin therapy, massage, and remedial gymnastics
Study: 21197917
Drug: Monthly videophone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly videophone healthy-lifestyle education calls (Control)
Study: 17081398
Drug: Elevated fibrinogen
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated fibrinogen (fibrinogen level > 4.0 g/L, n = 81)
Study: 17081398
Drug: Control fibrinogen
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control fibrinogen (fibrinogen level < or = 4.0 g/L, n = 104)
Study: 17081398
Drug: Elevated hs-CRP
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated hs-CRP (hs-CRP > 3.0 mg/L, n = 86)
Study: 17081398
Drug: Control hs-CRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control hs-CRP (hs-CRP < or = 3.0 mg/L, n = 99)
Study: 17081398
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of elevated fibrinogen and hs-CRP
Study: 12681023
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone (RSG) added to 2.5 g/day of metformin (MET)
Study: 10971048
Drug: Galantamine 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 32 mg/day
Study: 10971048
Drug: Galantamine 24
Normalized name: galantamine 24 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 24 mg/day (12-month study)
Study: 8997651
Drug: 0.2% hexetidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% hexetidine spray
Study: 1546121
Drug: Moclobemide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (150 mg, increased to 450 mg if necessary)
Study: 1546121
Drug: Fluvoxamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50 mg, increased to 200 mg if necessary)
Study: 31917233
Drug: Post-surgical targeted
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-surgical targeted antibiotic therapy for 2 weeks
Study: 29328007
Drug: Intravenous hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydration (0.9% NaCl)
Study: 26677057
Drug: Intact casein
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact casein infusion
Study: 26677057
Drug: Casein hydrolysate
Normalized name: casein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein hydrolysate infusion
Study: 24841647
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate solution instilled into the pelvic cavity (R-Group)
Study: 19087330
Drug: Multidisciplinary group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary group treatment (Go4it)
Study: 16160575
Drug: Frialit‐2 implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frialit‐2 implants or IMZ Twin Plus implants
Study: 11329114
Drug: Calcium citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium citrate (800 mg daily)
Study: 26054119
Drug: Chlortetracycline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlortetracycline treatment
Study: 26054119
Drug: Chlortetracycline +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlortetracycline + beclomethasone treatment
Study: 26054119
Drug: Beclomethasone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone treatment
Study: 11040246
Drug: Lacidipine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (4 mg once daily for 4 weeks)
Study: 1801333
Drug: Oral chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral chloroquine (nasogastric tube)
Study: 1801333
Drug: Intramuscular chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular chloroquine (3.5 mg/kg 8-hourly)
Study: 6591740
Drug: Diatrizoate (290
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diatrizoate (290 mg I/ml)
Study: 24681813
Drug: Multiple treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple treatment framework with different variants emphasizing monetary and non-monetary benefits and costs
Study: 23610561
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate infusion (5.1 mmol/kg for 24 hours)
Study: 23610561
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride infusion (5.1 mmol/kg for 24 hours)
Study: 21480703
Drug: Low-dose control
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose control condition
Study: 16984383
Drug: Oral bovine
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral bovine lactoferrin (bLF) at a dose of 1.8 g daily for 12 weeks
Study: 11074684
Drug: Enhanced care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced care with manual therapy
Study: 11074684
Drug: Enhanced care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced care with manual therapy (four or more maneuvers)
Study: 27893820
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg once daily for three days
Study: 1638586
Drug: Ofloxacin 200
Normalized name: ofloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 200 mg daily for three days
Study: 1638586
Drug: TMP/SMX 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP/SMX 160 mg/800 mg twice daily for seven days
Study: 6703672
Drug: Apalcillin (2-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalcillin (2-g dose, intravenous)
Study: 6703672
Drug: Piperacillin (2-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (2-g dose, intravenous)
Study: 24299662
Drug: EGCG (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG (300 mg/d)
Study: 17494794
Drug: Moli1901 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moli1901 (2.5 mg/d)
Study: 16645534
Drug: Methyltestosterone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyltestosterone (2.5 mg)
Study: 16645534
Drug: No hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormone therapy (placebo)
Study: 10606936
Drug: FPND 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPND 400 microg twice daily (b.i.d.)
Study: 10606936
Drug: FPND 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPND 400 microg once daily (o.d.)
Study: 10606936
Drug: FPND 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPND 400 microg once daily (o.d.) and FPND 400 microg twice daily (b.i.d.)
Study: 8891846
Drug: Levosulpiride (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosulpiride (25 mg tid)
Study: 8891846
Drug: Domperidone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (10 mg tid)
Study: 8891846
Drug: Metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (10 mg tid)
Study: 8891846
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet tid)
Study: 6359724
Drug: Aspirin (50-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (50-500 mg)
Study: 22742765
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of meropenem (2 g loading dose followed by 4 g continuous infusion over 24 hours)
Study: 22742765
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of meropenem (2 g over 30 minutes every 8 hours)
Study: 22742765
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of meropenem
Study: 22742765
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of meropenem
Study: 17620552
Drug: Initial pramipexole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial pramipexole treatment
Study: 11903069
Drug: Postoperative 6-hydroxymelatonin
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative 6-hydroxymelatonin sulphate excretion
Study: 8521893
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (orchiectomy plus placebo)
Study: 28295934
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300 U/mL (IGlar-U300) 0.4 U/kg once daily
Study: 26345920
Drug: High-intensity focused
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity focused ultrasound (HIFU) therapy under nasal endoscopy guidance
Study: 26345920
Drug: Corticosteroid nasal
Normalized name: Corticosteroid nasal preparations for topical use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid nasal spray and oral cetirizine hydrochloride (Control)
Study: 21311216
Drug: SPEEDA under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SPEEDA under Essen 5-dose regimen (group C)
Study: 17311051
Drug: Isoflavone supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone supplementation (70 mg/day for 24 weeks)
Study: 15321207
Drug: Left lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left lateral position for 10 min after injection
Study: 15321207
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (S, L, L+R)
Study: 8840055
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg esmolol
Study: 8840055
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg esmolol
Study: 3048753
Drug: Standard commercial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard commercial preparation of 0.5% bupivacaine
Study: 26006197
Drug: 2 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/kg PEG powder (17 g in 240 mL water or another beverage) and 5 mg bisacodyl suppository (BD) the day before colonoscopy
Study: 26006197
Drug: 1.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/kg PEG with fruit juices for two days and 5 mg bisacodyl suppository (BD) for two days before colonoscopy
Study: 8324855
Drug: Height-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Height-based dosing method
Study: 8324855
Drug: Physical appearance
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical appearance dosing method
Study: 25852131
Drug: Electrostimulation plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrostimulation plus low molecular weight heparin and below-knee compression stockings (Group 1)
Study: 25852131
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin and below-knee compression stockings alone (Group 2, control group)
Study: 18031471
Drug: Nortriptyline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (50 mg daily)
Study: 11915576
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg MPA
Study: 11915576
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg MPA
Study: 10736332
Drug: Isoflavone doses
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone doses of 0.8‐1.4 mg/kg
Study: 10736332
Drug: Isoflavone bioavailability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone bioavailability
Study: 9344322
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy for nonextremity sarcomas
Study: 1398472
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human GH (rhGH) treatment for 6 months
Study: 3998766
Drug: Synthetic thymosin-alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic thymosin-alpha 1 (loading dose regimen)
Study: 3998766
Drug: Synthetic thymosin-alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic thymosin-alpha 1 (twice‐weekly schedule)
Study: 30146344
Drug: VR942 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: VR942 0.5 mg
Study: 30146344
Drug: VR942 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: VR942 10 mg
Study: 30146344
Drug: VR942 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: VR942 20 mg
Study: 30146344
Drug: VR942 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: VR942 (all doses)
Study: 26834046
Drug: Active encouragement
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active encouragement for diagnostic testing and treatment
Study: 19962730
Drug: Intranasal desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal desmopressin spray (40 microg) plus diclofenac sodium suppository (100 mg)
Study: 19962730
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium suppository (100 mg) plus placebo spray (normal saline 0.9%)
Study: 18375325
Drug: Standard tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard tranexamic acid dosing regimen (10 mg/kg over 20 minutes, followed by 1 mg/kg/h)
Study: 18375325
Drug: New tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: New tranexamic acid dosing schedule
Study: 18375325
Drug: New dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: New dosing protocol for tranexamic acid
Study: 12795227
Drug: Tianbaokang Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianbaokang Injection
Study: 31054935
Drug: Taurolidine-citrate (T-C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurolidine-citrate (T-C) solution
Study: 27003917
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg load followed by a continuous infusion of 0.5 μg/kg/h)
Study: 25216660
Drug: Nonrestorative caries
Normalized name: Tilletia caries
DrugBank: Tilletia caries (DB10705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonrestorative caries treatment (NRCT; no caries removal, opening up the cavity, teaching brushing and fluoride application)
Study: 21908204
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) supplementation (600 mg daily for 8 weeks)
Study: 15729082
Drug: Risperidone (3.6±1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (3.6±1.5 mg/day)
Study: 3903787
Drug: Ranitidine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (0.6 g per day)
Study: 3903787
Drug: Triletide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triletide (2 g per day)
Study: 25226857
Drug: Controlled ovarian
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled ovarian hyperstimulation (COH) - IUI for group 2A (FSH 10-15 mIU/mL and E2<40 pg/mL)
Study: 25226857
Drug: Controlled ovarian
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled ovarian hyperstimulation (COH) - IUI for group 2B (FSH 10-15 mIU/mL and E2≥40 pg/mL)